Biodexa Pharmaceuticals (BDRX) announced the European Commission has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis. The company said the Phase 3 study of eRapa in FAP is in the final stages of implementation.
"This Orphan Drug Designation is another important step as we move our FAP program forward into a registrational Phase 3 study," said Stephen Stamp, CEO and CFO of Biodexa Pharmaceuticals.
Shares of Biodexa Pharmaceuticals are down 15% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com